Keywords
autonomic dysfunction, orthostatic intolerance, autoimmune, autonomic neuropathy
This article is included in the Emerging Diseases and Outbreaks gateway.
autonomic dysfunction, orthostatic intolerance, autoimmune, autonomic neuropathy
Postural tachycardia syndrome (POTS) results from autonomic dysregulation. It is characterized in adults by a clinically symptomatic, sustained increase in heart rate of more than 30 beats per minute within 10 minutes of standing or head-up tilt testing, in the absence of orthostatic hypotension.1,2 Patients with POTS experience symptoms of orthostatic intolerance in the upright position such as lightheadedness, dizziness, palpitations, tremulousness, generalized weakness and leg pain, blurred vision, dyspnea, nausea, headache and cognitive dysfunction.3–6 Many patients with POTS additionally report non-orthostatic symptoms of autonomic origin such as fatigue, gastrointestinal complaints, sleep disturbances, restless legs symptoms and exercise intolerance.7,8 The exact etiology of POTS is still unknown, although in recent years evidence has accumulated that in a subset of patients with POTS the pathogenesis of dysautonomia may be immune-mediated.9,10 The onset of POTS is frequently reported after an immunologic stressor, with a female predominance.11,12 Up to 50% of patients with POTS describe a viral infection as the trigger of their symptoms.12,13 Patients also often report that infections (especially viral illnesses) are triggers for a prolonged symptom exacerbation, even after the subsiding of the acute infection.4,13,14 Individuals with POTS are more likely to be affected by comorbid autoimmune diseases than the average population.8,15,16 In recent years, autoantibodies against G-coupled protein receptors, most often including autoantibodies against adrenergic and cholinergic receptors, were characterized in POTS.9,17–19 Autoantibodies against the α1-adrenergic receptor were the most common among them.18–20 Additionally, antibodies against angiotensin II type 1 receptors and abnormal levels of inflammatory biomarkers were reported.21,22 Despite the presence of these antibodies, their role in the complex pathophysiology of autonomic dysfunction in POTS remains unknown.15 Immunomodulatory treatment with intravenous immunoglobulins has shown a positive effect on the symptoms of patients with POTS, further supporting an immune-mediated genesis.23
In the wake of the coronavirus disease 2019 (COVID-19) pandemic, numerous case reports and case series about the occurrence of POTS following an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have accumulated.24–30 Nearly all affected individuals were females without pre-existing conditions who developed symptoms of autonomic dysfunction several days or weeks after an acute COVID-19 infection and there was no association with initial COVID-19 severity.24,31,32 Vaccines based on messenger ribonucleic acid (mRNA) technology are being used to combat the COVID-19 pandemic. The mRNA provides the body with the genetic code of the virus, which is then translated in the host cells and as a consequence, spike proteins are built. These act as antigens and trigger an immune response, as a result of which neutralizing antibodies against SARS-CoV-2 are formed.33 There is one case report in which POTS was diagnosed in a previously healthy, 42-year-old male following the first dose of mRNA vaccination.34
We have observed that patients with POTS are hesitant towards vaccination in general and especially towards the new mRNA vaccines because they often fear aggravation of their symptoms. On the other side, it is reasonable to assume that a COVID-19 infection in patients with POTS may trigger a prolonged symptom amplification as it is commonly observed with infections.
The aim of this study was to assess the tolerability and side effects of the two COVID-19 mRNA vaccines used in Switzerland (Spikevax®, Moderna; BNT162b2®, Pfizer) in a cohort of patients with POTS, and to assess possible consequences of a COVID-19 infection on POTS symptoms.
We conducted a standardized checklist-based interview with all patients who had been diagnosed with neuropathic POTS and were followed in the Autonomic Unit of the Departments of Neurology and Neurosurgery, University Hospital Bern, Bern, Switzerland. All available patients were contacted by telephone and asked if they were interested in participating in the study after checking the eligibility criteria. If interested, they were sent the informed consent form. After receiving the signed consent form the interview took place. The structured interviews were performed by one of two authors (KJ or BR) either by telephone or during a routine consultation. Data was collected between November 2021 and January 2022. All contacted patients agreed to participate in the study and provided written informed consent for the collection and publication of their data. Potential bias was minimized by the standardization and structuring of the interview. The interviewer strictly followed the predetermined interview checklist (please see the extended data for the used interview checklist).48 The study was carried out in accordance with the Declaration of Helsinki. The diagnosis of POTS had been made according to medical history, physical and neurological examination, cardiovascular autonomic function testing, thermoregulatory sweat test and/or quantitative testing of sudomotor axon reflex, determination of autoantibodies against G-protein-coupled receptors, measurement of plasma norepinephrine levels and skin biopsy in selected patients.1,35
Patients had to meet the following inclusion criteria: confirmed diagnosis of neuropathic POTS, aged between 18 and 60 years, received two COVID-19 mRNA vaccine doses ≥ 1 month prior to the interview, or recovered from COVID-19 infection ≥ 1 month prior to the interview.
To evaluate the tolerability of COVID-19 mRNA vaccines, the following data were collected during the interviews: Date(s) of vaccination and type of vaccine (BNT162b2®, Pfizer BioNTech, New York, NY or Spikevax®, Moderna, Cambridge, MA). The following, previously published side effects of vaccines36–38 were assessed (for the first and second dose of the vaccine separately) in their presence (yes/no) and duration (days): fever, shivering, fatigue, headache, joint pain, muscle pain, nausea, emesis, diarrhea, and reaction at injection site (pain, swelling and cutaneous reaction).49
In patients who had suffered a COVID-19 infection, the following additional symptoms were queried: coughing, sore throat, rhinorrhea, breathlessness, loss of taste, loss of smell and chest pain. For each symptom, the presence (yes/no), severity (mild, moderate, severe) and duration (in days) were evaluated. Furthermore, the duration of the infection, need for hospitalization and incapacity for work were assessed.
To assess possible exacerbation of POTS symptoms due to mRNA vaccination and COVID-19 infection, the presence (yes/no), severity (mild, moderate, severe; for COVID-19 infection only) and duration of symptom exacerbation (in days) for the following symptoms were evaluated: dizziness, nausea, weakness, palpitations, lightheadedness, tremulousness, blurred vision, concentration difficulties, memory difficulties, orthostatic leg and/or arm pain, gastrointestinal symptoms, sleep disturbances, restless legs syndrome and orthostatic headache. During the interview, symptom aggravation was assessed separately for the first and second dose of the vaccine, and COVID-19 infection, from the patients memory. Furthermore, adjustment of therapy and inability for work due to symptom exacerbation were assessed.
The data analysis was descriptive and performed using Statistical Package for the Social Sciences (SPSS Statistics) Version 25.0 (IBM Corp., Armonk, NY, USA). Data are reported either as frequencies, mean (range) or median (range). All interviews were fully completed, so there were no missing data.
A total of 23 patients, two men (8.7%) and 21 women (91.3 %) with diagnosed neuropathic POTS and a mean age of 26.65 (range 18-40) years, were included in this study and interviewed once. In total, 20 patients who had been vaccinated twice and had not previously suffered a COVID-19 infection were assessed for side effects of the vaccinations. Of the 23 patients included in this study five (21.7%) had suffered a COVID-19 infection; three before and two after two doses of mRNA vaccination.48
Frequencies of published acute side effects of mRNA vaccination reported by our POTS cohort are shown in Table 1. All included patients received the first dose between April and September 2021 and the second dose between May and October 2021. After the first dose, patients were unable to work for a mean of 0.35 (range 0-7) days and after the second dose for a mean of 1.05 (range 0-3) days. No allergic reactions were observed.
Acute symptoms of COVID-19 infection are summarized in Table 2. Mean duration of infection was 16.4 (range 10 – 27) days. None of the patients had to be hospitalized. Mean duration of incapacity for work was 18.8 (range 10 – 28) days.
Patient 1 | Patient 2 | Patient 3 | Patient 4* | Patient 5* | ||
---|---|---|---|---|---|---|
Age | 22 | 28 | 27 | 24 | 26 | |
Sex | Male | Female | Female | Female | Female | |
Symptom | ||||||
Fever | Presence | Severe | No | Moderate | No | Moderate |
Duration | 18 days | - | 4 days | - | 5 days | |
Shivering | Presence | Severe | No | Moderate | Moderate | No |
Duration | 7 days | - | 4 days | 3 days | - | |
Fatigue | Presence | Severe | Severe | Severe | Severe | Severe |
Duration | 1 month | 20 days | 21 days | 18 days | 14 days | |
Headache | Presence | Severe | Mild | Moderate | Moderate | Moderate |
Duration | 14 days | 14 days | 21 days | 4 days | 6 days | |
Joint pain | Presence | No | Mild | Moderate | Moderate | Severe |
Duration | - | 4 days | 21 days | 5 days | 3 days | |
Muscle pain | Presence | Moderate | Mild | Moderate | Moderate | No |
Duration | 14 days | 4 days | 21 days | 5 days | - | |
Nausea | Presence | Severe | No | Moderate | Moderate | Severe |
Duration | 1 month | - | 12 days | 7 days | 3 days | |
Emesis | Presence | Severe | No | No | Mild | No |
Duration | 1 month | - | - | 1 day | - | |
Diarrhea | Presence | Moderate | No | Severe | Moderate | Moderate |
Duration | 4 days | - | 18 days | 6 days | 3 days | |
Coughing | Presence | Moderate | Mild | Moderate | Mild | No |
Duration | 14 days | 2 days | 21 days | 6 days | - | |
Sore throat | Presence | Moderate | Severe | Moderate | Moderate | No |
Duration | 7 days | 2 days | 21 days | 7 days | - | |
Rhinorrhea | Presence | No | Mild | Mild | Severe | Moderate |
Duration | - | 2 days | 6 days | 7 days | 5 days | |
Breathlessness | Presence | Severe | No | Moderate | No | Moderate |
Duration | 14 days | - | 21 days | - | 5 days | |
Loss of taste | Presence | Severe | No | Severe | Mild | No |
Duration | 3 months | - | 5 months | 1 day | - | |
Loss of smell | Presence | Moderate | Severe | Moderate | No | No |
Duration | 3 months | 1 month | 2 months | - | - | |
Chest pain | Presence | No | No | Mild | No | Moderate |
Duration | - | - | 21 days | - | 5 days |
Reported increase of POTS symptoms after mRNA vaccination is shown in Table 3. An increase of POTS symptoms was reported by three patients after the first and by five patients after the second vaccination. Mean duration of symptom increase was seven days (range 1-14). None of the patients needed an adjustment of the symptomatic therapy for POTS, and no incapacity for work was reported.
The effects of COVID-19 infection on POTS symptoms are shown in Table 4. In addition to the above reported incapacity for work, one patient (Patient 3) had to reduce her existing workload for two more months. Adjustment of symptomatic POTS treatment was necessary in all patients.
Patient 1 | Patient 2 | Patient 3 | Patient 4* | Patient 5* | ||
---|---|---|---|---|---|---|
Age | 22 | 28 | 27 | 24 | 26 | |
Sex | Male | Female | Female | Female | Female | |
Symptom increase | ||||||
Dizziness | Presence | Mild | Moderate | Mild | Moderate | Moderate |
Duration | Persistent | 1 month | 4 months | 1 month | 1 week | |
Nausea | Presence | No | No | No | No | Mild |
Duration | - | - | - | - | 5 weeks | |
Weakness | Presence | Mild | Moderate | Moderate | Mild | Mild |
Duration | Persistent | 1 month | 4 months | 1 month | 5 weeks | |
Palpitations | Presence | No | Mild | Mild | No | No |
Duration | - | 5 months | 2 months | - | - | |
Lightheadedness | Presence | No | No | Mild | No | Mild |
Duration | - | - | 6 months | - | 5 weeks | |
Tremulousness | Presence | No | No | No | No | No |
Duration | - | - | - | - | - | |
Blurred vision | Presence | No | No | Mild | No | No |
Duration | - | - | 6 months | - | - | |
Concentration difficulties | Presence | Severe | Moderate | Moderate | No | Mild |
Duration | Persistent | 1 month | 6 months | - | 5 weeks | |
Memory difficulties | Presence | No | No | No | No | No |
Duration | - | - | - | - | - | |
Orthostatic arm and/or leg pain | Presence | Moderate | Moderate | Mild | Moderate | No |
Duration | Persistent | 1 month | 4 months | 1 month | - | |
Gastrointestinal symptoms | Presence | No | No | Severe | Mild | Moderate |
Duration | - | - | 3 months | 1 month | 5 weeks | |
Sleep disturbances | Presence | Severe | No | No | No | Moderate |
Duration | Persistent | - | - | - | 5 weeks | |
Restless legs syndrome | Presence | Moderate | No | No | No | No |
Duration | Persistent | - | - | - | - | |
Orthostatic headache | Presence | Mild | No | Mild | No | No |
Duration | Persistent | - | Persistent | - | - |
The present study investigated the frequencies of known side effects of mRNA vaccination (Spikevax®, Moderna; BNT162b2®, Pfizer) in patients with POTS. In addition, possible effects on POTS symptoms were assessed and compared to the impact of a COVID-19 infection.
Vaccine side effects were present in 20 (100%) patients for both vaccinations. The most frequently reported side effects of mRNA vaccines were pain at the injection site (70% after first, 85% after second), fatigue (50% after first, 80% after second), headache (30% after first, 75% after second), fever (20% after first, 65% after second) and shivering (15% after first, 65% after second). Side effects were generally reported more frequently after the second vaccination. This is in line with the results of other studies investigating the side effects of mRNA vaccines on healthy subjects as well as with the data from the vaccine manufacturers.33,36–38
Only six patients reported mild worsening of their POTS symptoms after vaccination beyond the duration of the acute side effects, for a mean duration of seven days (maximum 14 days). The observed increase in symptoms occurred more frequently after the second vaccination. This is similar to findings of studies examining the effects of mRNA vaccination on disease activity in patients with autoimmune inflammatory rheumatic diseases, which showed no higher incidence of side effects compared to healthy subjects and no greater risk of disease flares.39,40 Similarly, also patients who suffered from post-COVID symptoms of dysautonomia did not report a worsening of symptoms after getting vaccinated.41
In contrast, patients suffering a COVID-19 infection experienced a pronounced and prolonged aggravation of their POTS symptoms for several months. Due to the symptom increase all patients needed an adjustment of their symptomatic POTS therapy and had prolonged incapability for work. Interestingly, symptom exacerbation due to a COVID-19 infection was also observed in two previously vaccinated patients. However, both patients were vaccinated more than six months prior to the infection at a time when booster vaccinations were not yet available for this priority group in Switzerland. In these two patients, there was a tendency for a milder and shorter exacerbation of POTS symptoms compared to non-vaccinated patients.
Most patients with POTS experience a prolonged increase of their symptoms in the context of infections (especially of viral etiology).4,13,14 In general, hypovolemia, fever and bedrest can intensify POTS symptoms.26,42,43 Furthermore, in patients with possible immune-mediated POTS, symptom aggravation is most likely due to a general immunological activation. Besides this, SARS-CoV-2 appears to affect the autonomic nervous system directly, which could be an additional factor for aggravation.44 Since the onset of the COVID-19 pandemic, an increasing number of case reports about the occurrence of POTS secondary to a COVID-19 infection have emerged.24–30 Several hypotheses about possible pathomechanisms of POTS or dysautonomia in general after COVID-19 infection have been proposed: imbalance of the renin-angiotensin-aldosterone system,26,29 brainstem involvement,43,45,46 autoreactivity to antibodies against SARS-CoV-2,25,43,47 dyshomeostasis of immune response42,44 and denervation of peripheral sympathetic nerve fibers. 26,43,42
This study has some limitations. Due to the small number of cases (especially of POTS patients with COVID-19 infection), generalizability cannot be fully derived. Furthermore, the retrospective collection of data by interview bears the risk of inaccurate symptom recollection and reporting in patients. Finally, effects of mRNA booster vaccinations and other types of vaccination were not recorded in this study.
The observations of this study suggest that mRNA vaccines are not associated with a higher incidence of acute side effects in patients with POTS and only pose a mild to moderate risk for POTS symptom exacerbation, usually of short duration. POTS symptom exacerbation as a consequence of mRNA vaccination was milder and of shorter duration compared to patients who suffered a COVID-19 infection.
Dryad: Tolerability of COVID-19 mRNA vaccines in patients with postural tachycardia syndrome https://doi.org/10.5061/dryad.zkh1893bx.48
This project contains the following underlying data:
- Demographic_data.xlsx
- POTS_symptoms_after_COVID-19.xlsx
- POTS_symptoms_after_vaccination.xlsx
- Side_effects_of_mRNA_vaccines.xlsx
- Symptoms_of_COVID-19_infection.xlsx
Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).
Zenodo: Tolerability of COVID-19 mRNA vaccines in patients with postural tachycardia syndrome https://doi.org/10.5281/zenodo.5925527.49
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Postural tachycardia syndrome related to COVID-19 desease or related to mRNA vaccinatio
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 22 Feb 22 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)